Image source: Dr Michael May/Dr Wungki Park/Memorial Sloan Kettering Cancer Center/Press Association

Experts describe this treatment as the biggest breakthrough in treating pancreatic cancer in decades.

This treatment is a daily pill that appears to help shrink tumors, and possibly eliminate them, in some patients with one of the deadliest and most difficult to treat types of cancer.

Early clinical trials showed that the cancer became undetectable on scans in 1 in 12 patients who received daraxonraceb in combination with chemotherapy.

Tumors stopped growing in nearly all of the trial's 61 participants who were newly diagnosed with advanced pancreatic cancer after the disease had spread to other parts of the body.

But doctors stress that it is still unclear how long treatment can keep the disease under control, stressing that it should not be considered a final treatment for cancer.

"The results are very exciting"

Cancer Research UK described it as “the biggest leap forward in decades” for pancreatic cancer patients.

Dr Sam Godfrey from the charity told BBC News the results were very exciting. “What this new drug did was provide a way to treat what was considered untreatable with drugs.”

He continued: "We are finally witnessing progress in treating pancreatic cancer, which is something that has been long awaited."

Most read end

Pancreatic cancer is notoriously difficult to treat and has the lowest survival rate of all common cancers in the UK.

Although chemotherapy may shrink tumors slightly, the cancer often grows again.

Most patients with advanced disease live for months, not years.

Doctors hope the new treatment will buy patients more time, even if it cannot stop the cancer completely.

Patients' experience lasted an average of a year and a half, and some did not see their cancer return during this period.

Longer studies are needed to understand whether any of these cancers can be put into remission, and for how long.

In the first/second phase of the trial:

"Stay longer"

Image source: Getty Images

Stay updated with the latest current affairs

Download the app

BBC Arabic application for mobile phones

Dr Wongki Park, from Memorial Sloan Kettering Cancer Center in the US, who is involved in the trial, said the results so far are very encouraging.

He added: "We are beginning to notice not only an increase in tumor response rates to treatment, but also deeper responses, and an almost doubling of the duration of disease control, which may ultimately be reflected in a longer life for patients."

Daraxonraceb, an inhibitor-targeted therapy, has already received approval for use in the United States. It works by binding to certain genetic mutations known as RAS and inhibiting their activity.

These mutations are found in most cases of pancreatic cancer, and play a role in stimulating the growth of tumors.

Similar mutations could also appear in dozens of other types of cancer, including lung and ovarian cancer, opening up the possibility that other patients could benefit from this drug.

“I hope that the early success we are starting to see in treating pancreatic cancer will extend to other cancers as well,” Dr. Godfrey said.

But he stressed the importance of conducting longer trials and following up on their results, adding: “Cancer may reappear, and even if the tests do not reveal any trace of it, this does not necessarily mean that the patient has been completely cured of it. Confirming this requires more time.”

Professor Elena Garalda, President of the European Cancer Research Congress (EORTC–NCI–AACR Symposium 2026), during which the results of the study will be presented to doctors and researchers, said that these results are interesting, because they indicate that combining the two treatments may contribute to significantly improving patients’ survival rates, as well as prolonging the period in which tumors remain under control before they begin to grow again.

Pancreatic cancer represents about 3 percent of all cancer cases in the United States, and about 8 percent of cancer deaths in the United States, as it causes the death of approximately 53 thousand people annually.

In Britain, about 11,500 cases of pancreatic cancer are recorded annually, while the disease causes about 10,200 deaths every year, according to Cancer Research UK.

British actor Alan Rickman died of pancreatic cancer in 2016, five months after being diagnosed with the disease.

Symptoms of pancreatic cancer may include jaundice or yellowing of the skin and eyes, itching of the skin, a change in the color of urine to dark and stool to light, as well as weight loss for no apparent reason, feeling tired, and high temperature.

We used artificial intelligence to help translate this article, which was originally written in English. This translation was reviewed by a BBC journalist before publication. More about how we use AI.

Find out more

Short clips

End of short clips

Main news

Saudi Arabia announces the interception of new ballistic missiles launched by the Houthis over Riyadh

“The far right threatens Europe, but it is fragile” - article in The Guardian

Is infrastructure turning into a weapon of war in conflict areas?

We chose for you

Readers' preferences